Intellia Therapeutics, Inc. (NTLA)
NASDAQ: NTLA · Real-Time Price · USD
11.60
-0.49 (-4.05%)
At close: Aug 18, 2026, 4:00 PM EDT
11.97
+0.37 (3.19%)
Pre-market: Aug 19, 2026, 9:16 AM EDT

Intellia Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
59.5167.6757.8836.2852.1233.05
Revenue Growth
12.58%16.92%59.55%-30.40%57.69%-43.01%
Gross Profit
-222.82-256.78-349.04-398.79-367.86-196.75
Operating Income
-423.48-440.99-534.26-515.29-458.16-267.85
Net Income
-399.98-412.69-519.02-481.19-474.19-267.89
Earnings Per Share
-3.34-3.81-5.25-5.42-6.16-3.78
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
628.35605.13861.731,0121,2621,086
Total Debt
73.4193.33210.2115.35130.774.02
Net Cash (Debt)
554.94511.81651.53896.741,1311,012
Net Cash Growth
5.12%-21.45%-27.34%-20.73%11.78%81.34%
Net Cash Per Share
4.644.726.5910.1014.7014.28

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-346.64-394.74-348.88-394.09-333.29-225.03
Capital Expenditures
-2.04-1.13-5.78-13.99-13.56-12.76
Free Cash Flow
-348.69-395.87-354.66-408.07-346.85-237.79
Free Cash Flow Growth
------

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
------
Operating Margin
-711.66%-651.67%-923.10%-1420.51%-879.04%-810.37%
Pretax Margin
-672.16%-609.85%-896.77%-1326.51%-909.78%-810.49%
Profit Margin
-672.16%-609.85%-896.77%-1326.51%-909.78%-810.49%
FCF Margin
-585.97%-584.99%-612.78%-1124.94%-665.46%-719.41%

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
27.3215.3920.5275.2757.06266.22